Question 1

I have Hashimoto's. Does the warning apply to me?

Accepted Answer

No, and these two conditions have almost nothing to do with each other beyond sharing an organ. Hashimoto's is an autoimmune attack on the follicular cells that make thyroid hormone, which is why it causes hypothyroidism. The warning concerns the C-cells, a different cell population entirely, and the cancer it names makes up only about 1-2% of thyroid malignancy. The label excludes exactly one thing: having medullary thyroid cancer or MEN 2 in your own history or your family's. Hashimoto's is not on that list, and neither high antibody levels nor active hypothyroidism on replacement puts you there. In two large observational studies summarized by the 2024 Thyroid review, autoimmune thyroid disease did not change the thyroid cancer estimate. Enormous numbers of people with Hashimoto's take these drugs on stable replacement. What does apply to you is the levothyroxine question further down. Disclose the diagnosis, get a baseline TSH, and expect to recheck it.

Question 2

Will this change my levothyroxine?

Accepted Answer

Very likely, and in a direction you should measure rather than guess. These drugs hold food in the stomach longer as part of how they work, and levothyroxine is unusually sensitive to that, because it needs an acidic, empty stomach to be absorbed predictably. A 2025 pharmacokinetics review lists it among the oral drugs whose absorption can shift after starting a GLP-1. Two published case reports show the pattern in practice. One patient after thyroidectomy developed suppressed TSH (looking over-replaced) after starting semaglutide and needed the levothyroxine dose cut, and a second, six months into tirzepatide, reached the emergency department over-replaced and was managed by cutting the levothyroxine, with advice to space the tirzepatide doses further apart rather than stop it. Reported cases skew toward suppression, but weight loss itself lowers your dose requirement too, so the net direction varies from patient to patient. The practical rule endocrinologists use: recheck TSH six to eight weeks after starting, and again after each 10-15% change in body weight. Keep taking levothyroxine exactly as before.

Question 3

Can I take these if my family has medullary thyroid cancer or MEN 2?

Accepted Answer

No. This is the one absolute exclusion, it is written into the label of every drug in the class, and it applies whether or not you personally have ever been tested or diagnosed. Two things support it. In rodent studies, semaglutide, liraglutide and tirzepatide all produced C-cell tumors of the thyroid in a way that scaled with dose and duration. And MEN 2 is driven by an inherited RET mutation that already primes exactly that cell lineage toward malignancy, so the rodent tumors and the inherited risk involve the same cell type. Every registration trial in this class enforced the same exclusion, from the cardiovascular outcomes trial through the obesity programs, so there is no trial population that can tell you what happens if you take it anyway. If you discover the family link after starting, the usual path is to stop the drug, see a genetic counselor, consider testing for the RET mutation, and ask endocrinology what else is available to you.

Question 4

I have a thyroid nodule. Do I have to stop?

Accepted Answer

Almost certainly not, and this is one of the commonest unnecessary stops. Nodules turn up in something like one adult in two once you scan carefully for them, and none of these labels lists a nodule as a contraindication. The exclusion names medullary thyroid carcinoma and MEN 2 specifically, and nothing else. Most nodules are benign, and the standard workup characterizes them by ultrasound features with selective biopsy where size and risk features warrant it. That process is unchanged by being on a GLP-1. A 2024 review in Thyroid found no conclusive evidence of raised thyroid cancer risk in people and said nodules should be evaluated by the usual guidelines, with no evidence supporting screening for them before or during treatment. A large Scandinavian registry cohort found no overall thyroid cancer signal against a comparator drug class. Disclose the nodule, hand over the ultrasound report, a recent TSH and any calcitonin, and let endocrinology set the surveillance interval.

Question 5

My TSH dropped. Is the drug making me hyperthyroid?

Accepted Answer

Almost certainly not. What is usually happening is that your effective levothyroxine dose has changed, not that your thyroid has. Two forces do it: altered absorption from a slower stomach, and weight loss reducing how much hormone you need, since replacement is dosed roughly by body weight. Published post-thyroidectomy cases show exactly this after both semaglutide and tirzepatide, and both were handled by adjusting the levothyroxine rather than stopping the GLP-1. Reported cases skew toward TSH suppression, the pattern of someone over-replaced, which fits a dose that has quietly become too large for a smaller body. The mistake to avoid is stopping an effective drug over one abnormal result. Recheck on a steady dose, bring your weight history so the prescriber can see the trajectory, and let endocrinology adjust the levothyroxine.

Question 6

Is there actual human evidence for thyroid cancer?

Accepted Answer

Inconsistent, and closer monitoring of people on these drugs may explain a good part of it. The boxed warning itself rests on rodent C-cell biology, not on human outcomes. In humans, a 2023 French case-control study using national insurance data reported raised risk of thyroid cancer overall and of medullary cancer specifically at one to three years of exposure, though the 2024 Thyroid review notes its medullary cases were identified indirectly and may be misclassified. But a larger Scandinavian cohort across three national registries, following users for an average of 3.9 years against a comparator drug class, found no overall increase. A 2024 cohort examining 13 obesity-associated cancers found no thyroid signal either. Pooling randomized trials, a 2025 meta-analysis found no overall cancer signal but did find a raised thyroid cancer estimate (odds ratio 1.55), more evident in longer trials. The 2024 Thyroid review found no conclusive evidence of raised risk and judged the observational studies inconsistent and at high risk of bias, with surveillance bias not thoroughly assessed. The last answer on this page looks at that bias.

Question 7

I had papillary thyroid cancer. Am I excluded?

Accepted Answer

No, and the distinction is biological rather than a technicality. Papillary cancer is about 80% of thyroid malignancy and arises from follicular cells; medullary cancer arises from the C-cells, which is the lineage the rodent findings concern. The boxed warning names medullary disease and MEN 2, not papillary, follicular or Hürthle cell. The 2024 Thyroid review called the risk of these non-medullary cancers unproven and judged that for most patients the benefits of treatment are likely to outweigh it. The consideration that does apply to you is dosing. If you are on TSH-suppressive levothyroxine, both altered absorption and weight loss can move your TSH, which matters more when the target range is deliberately narrow. Published post-thyroidectomy cases show this being managed by dose adjustment, not by stopping. Confirm the pathology was not medullary, share recent thyroglobulin and surveillance imaging, and recheck TSH six to eight weeks after starting and after each 10-15% weight change.

Question 8

Is the warning the same on all of them?

Accepted Answer

Effectively identical across the injectable GLP-1 and dual GIP/GLP-1 drugs with US labels. Each states that the drug produced C-cell tumors of the thyroid in rats at exposures relevant to human dosing, that whether it does so in humans is unknown, and that it must not be used by anyone whose own or family history includes medullary thyroid cancer or MEN 2. Each also requires the prescriber to tell you which symptoms to report: a lump in the neck, trouble swallowing, breathlessness, or hoarseness that will not go away. The oral drugs carry it too. Rybelsus has it by class, and Foundayo, approved in April 2026, sets out the same exclusion in its own labeling, though worded differently: orforglipron did not produce tumors in rodents, so its warning rests on the findings for the rest of the class. No member of this class escapes the exclusion, so switching molecules is not a route around it.

Question 9

Do I need a baseline calcitonin or ultrasound first?

Accepted Answer

No. Routine calcitonin screening does more harm than good here, so know that before someone sells it to you. No label in this class requires either test. What the label does require is that your prescriber tells you which symptoms to report and evaluates you if they appear. The 2024 Thyroid review pointed to the EXSCEL trial, where routine calcitonin monitoring flagged 70 people, about half went on to further testing, and no additional thyroid cancers turned up. A raised calcitonin in someone with no medullary risk is far more likely to be a false alarm than a cancer, and the workup that follows is not harmless. What does belong in a sensible baseline: a TSH, particularly with any thyroid history; documentation of known nodules or prior surgery; and a careful family history that asks specifically about medullary cancer and MEN 2. A parent, sibling or child with either one means you are excluded.

Question 10

Is the extra cancer real, or just more scans?

Accepted Answer

Detection bias is the leading explanation for the observational signals. Someone started on one of these drugs sees endocrinology more often, gets more baseline labs, and gets more imaging. Each of those raises the chance of catching an incidental nodule or an early, quiet thyroid cancer that would otherwise have gone unnoticed for years. Finding more is not the same as causing more. The 2024 Thyroid review flagged surveillance bias as an important problem the studies had not thoroughly assessed, and noted that thyroid cancer is a diagnosis especially prone to over-detection. The test of that theory is what happens when surveillance is comparable between groups. The Scandinavian registry cohort, which compared against another actively managed drug class, found no overall increase, and the 13-cancer cohort found no thyroid signal either. The 2025 randomized-trial meta-analysis is the exception, with a raised thyroid cancer estimate that its authors say needs dedicated study. None of this retires the boxed warning, which rests on different evidence entirely.

GLP-1s and Your Thyroid: 10 Questions About the Boxed Warning

Q1.I have Hashimoto's. Does the warning apply to me?

Q2.Will this change my levothyroxine?

Q3.Can I take these if my family has medullary thyroid cancer or MEN 2?

Q4.I have a thyroid nodule. Do I have to stop?

Q5.My TSH dropped. Is the drug making me hyperthyroid?

Q6.Is there actual human evidence for thyroid cancer?

Q7.I had papillary thyroid cancer. Am I excluded?

Q8.Is the warning the same on all of them?

Q9.Do I need a baseline calcitonin or ultrasound first?

Q10.Is the extra cancer real, or just more scans?

References

Questions and answers